Chronic Closed-Angle Glaucoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CHR054 MIFTS: 32	Chronic Closed-Angle Glaucoma Categories: Eye diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Chronic Closed-Angle Glaucoma

MalaCards integrated aliases for Chronic Closed-Angle Glaucoma:

Name: Chronic Closed-Angle Glaucoma ¹² ¹⁵

Anatomical Narrow Angle Glaucoma ¹² ⁷¹

Chronic Angle-Closure Glaucoma ¹² ⁵⁴

Secondary Angle-Closure Glaucoma - Synechial ⁷¹

Chronic Narrow Angle Glaucoma ¹²

Classifications:

MalaCards categories:
Anatomical: Eye diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:14445

ICD9CM ³⁴ 365.23

SNOMED-CT ⁶⁷ 15417005 33647009

ICD10 ³² H40.22

UMLS ⁷¹ C0154947 C1272657

Sources

Summaries for Chronic Closed-Angle Glaucoma

MalaCards based summary : Chronic Closed-Angle Glaucoma, also known as anatomical narrow angle glaucoma, is related to open-angle glaucoma and acute closed-angle glaucoma. An important gene associated with Chronic Closed-Angle Glaucoma is TGFB2 (Transforming Growth Factor Beta 2), and among its related pathways/superpathways is ECM proteoglycans. The drugs Pilocarpine and Latanoprost have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and endothelial.

Sources

Related Diseases for Chronic Closed-Angle Glaucoma

Diseases in the Acute Closed-Angle Glaucoma family:

Chronic Closed-Angle Glaucoma

Diseases related to Chronic Closed-Angle Glaucoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 44)

#	Related Disease	Score	Top Affiliating Genes
1	open-angle glaucoma	30.6	TGFB2 MYOC LOXL1
2	acute closed-angle glaucoma	30.6	MYOC LAMA3 CTSA
3	glaucoma, primary open angle	30.6	TGFB2 MYOC LOXL1
4	intraocular pressure quantitative trait locus	30.2	TGFB2 MYOC LOXL1 CTSA
5	corneal edema	30.2	MYOC LAMA3
6	ocular hypertension	29.9	TGFB2 MYOC
7	cataract	10.7
8	primary angle-closure glaucoma	10.5
9	optic nerve disease	10.5
10	myopia	10.3
11	weill-marchesani syndrome	10.3
12	microphthalmia	10.3
13	neovascular glaucoma	10.2	TGFB2 NARF
14	glaucoma-related pigment dispersion syndrome	10.2	MYOC LOXL1
15	juvenile glaucoma	10.1	MYOC LOXL1
16	retinal detachment	10.1
17	retinitis pigmentosa	10.1
18	yemenite deaf-blind hypopigmentation syndrome	10.1
19	microvascular complications of diabetes 5	10.1
20	weill-marchesani syndrome 4	10.1
21	microcephaly, epilepsy, and diabetes syndrome	10.1
22	spastic paraplegia, intellectual disability, nystagmus, and obesity	10.1
23	exudative vitreoretinopathy	10.1
24	brachydactyly	10.1
25	neuroretinitis	10.1
26	lens subluxation	10.1
27	uveitis	10.1
28	retinal vein occlusion	10.1
29	central retinal vein occlusion	10.1
30	phimosis	10.1
31	retinitis	10.1
32	macular retinal edema	10.1
33	eye disease	10.1
34	scotoma	10.1
35	iridocyclitis	10.1
36	refractive error	10.1
37	vitreoretinopathy	10.1
38	iris disease	10.0	MYOC LOXL1
39	phacogenic glaucoma	10.0	NARF MYOC LOXL1
40	primary congenital glaucoma	10.0	MYOC LOXL1
41	aqueous misdirection	9.9	NARF LAMA3 CTSA
42	glaucoma, normal tension	9.9	MYOC LOXL1
43	lens disease	9.9	MYOC LOXL1 LAMA3
44	oculodentodigital dysplasia	9.9	PANX3 PANX2

Comorbidity relations with Chronic Closed-Angle Glaucoma via Phenotypic Disease Network (PDN):

Glaucoma, Primary Open Angle

Hypertension, Essential

Graphical network of the top 20 diseases related to Chronic Closed-Angle Glaucoma:

Sources

Symptoms & Phenotypes for Chronic Closed-Angle Glaucoma

Sources

Drugs & Therapeutics for Chronic Closed-Angle Glaucoma

Drugs for Chronic Closed-Angle Glaucoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 23)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Pilocarpine

Approved, Investigational

Phase 4

92-13-7, 54-71-7

5910

Synonyms:

(+)-Pilocarpine

(3S,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one

(3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one

(3S,4R)-3-ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone

(3S,4R)-3-ethyldihydro-4-((1-Methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone

(3S-cis)-3-Ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone

(3S-cis)-3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone

(3S-cis)-3-ethyldihydro-4-[(1-Methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone

3-ethyl-4-((1-methyl-1H-imidazol-5-yl)methyl)dihydro-2(3H)-furanone

3-Ethyl-4-(3-methyl-3H-imidazol-4-ylmethyl)dihydrofuran-2-one

3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydro-2(3H)-furanone

3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one

3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one

54-71-7

91484-73-0

92-13-7

AC1L1J0W

AC1L1LEF

AC1Q6MOP

Adsorbocarpine

AI3-50523

Almocarpine

Amistura P

AR-1F3128

beta-Pilocarpine hydrochloride

BIDD:GT0217

BPBio1_000548

BRD-K85090592-008-05-2

BSPBio_000498

BSPBio_002191

C07474

CHEBI:39460

CHEBI:8207

CHEMBL550

CID4819

CID5910

D00525

DB01085

DivK1c_000358

EINECS 202-128-4

Epicar

HMS2089K17

HSDB 3163

Hydrochloride, pilocarpine

IDI1_000358

Imidazole-5-butyric acid, alpha-ethyl-beta-(hydroxymethyl)-1-methyl-, gamma-lactone

isopilocarpine

Isopilocarpine

Isopto carpine

Isoptocarpine

KBio1_000358

KBio2_001587

KBio2_004155

KBio2_006723

KBio3_001691

KBioGR_000956

KBioSS_001587

L001181

Lopac0_000950

Lopac0_000960

LS-187208

LS-7661

Minims Pilocarpine

Miocarpine

Mi-Pilo

MolPort-002-512-506

NCGC00023339-03

NCGC00023339-06

NCGC00023339-07

NCGC00023339-08

NCGC00023339-09

NCGC00023339-12

NCGC00023339-13

nchembio.78-comp9

NCI60_004403

NINDS_000358

Nitrate, pilocarpine

NSC5746

Ocu-Carpine

Ocusert

Ocusert P 20

Ocusert pilo

Ocusert pilo-20

Ocusert pilo-20 (TN)

Ocusert Pilo-40

P.V. Carpine Liquifilm

Pilagan

Pilocarpin

Pilocarpina

pilocarpine

Pilocarpine

Pilocarpine (JAN/USP)

Pilocarpine [USAN:BAN:JAN]

Pilocarpine chloride

Pilocarpine HCl

Pilocarpine HCL

Pilocarpine hydrochloride

Pilocarpine monohydrochloride

Pilocarpine mononitrate, (3S-cis)-isomer

Pilocarpine Mononitrate, (3S-cis)-Isomer

Pilocarpine muriate

Pilocarpine nitrate

Pilocarpine, monohydrochloride, (3S-cis)-isomer

Pilocarpine, Monohydrochloride, (3S-cis)-Isomer

Pilocarpol

Pilokarpin

Pilokarpin monohydrochloride

Pilokarpol

Piloptic-1

Piloptic-1/2

Piloptic-2

Piloptic-3

Piloptic-4

Piloptic-6

Pilostat

Prestwick0_000449

Prestwick1_000449

Prestwick2_000449

Prestwick3_000449

Salagen

SDCCGMLS-0003164.P005

SPBio_001287

SPBio_002437

Spectrum_001107

Spectrum2_001284

Spectrum3_000546

Spectrum4_000478

Spectrum5_001379

Spersacarpine

Spersacarpine hydrochloride

STOCK1N-18408

Syncarpine

Tocris-0694

UNII-01MI4Q9DI3

ZINC00075008

Latanoprost

Approved, Investigational

Phase 4

130209-82-4

5282380 5311221

Synonyms:

130209-82-4

AC1NSK8Q

Ambap130209-82-4

AR-202

Catioprost

CHEBI:6384

CHEMBL1051

CID5311221

CPD000466354

D00356

HMS2051H11

HMS2089J17

isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate

Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate

isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate

Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate

Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoic acid

Jsp001835

L1167_SIGMA

latanoprost

Latanoprost

Latanoprost (JAN/USAN/INN)

latanoprost free acid

Latanoprostum

MLS000759468

MLS001424106

MolPort-003-942-862

Nova-21027

Pfizer brand OF latanoprost

PhXA 41

PhXA34

PhXA34 [as 15(R,S)-isomer]

PhXA41

PHXA41

PHXA-41

propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate

Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate

Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoic acid

propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate

S1254_Selleck

SAM001246671

SMR000466354

TL8000716

XA41

XA-41

Xalatan

Xalatan (TN)

Xalatan Fixed Flow Device

ZINC12468792

Travoprost

Approved

Phase 4

157283-68-6

5282226

Synonyms:

(((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester

(+)-Fluprostenol isopropyl ester

(1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-Dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester

(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3R)-3-hydroxy-4-((alpha,alpha,alpha-trifluoro-m-isopropyl-tolyl)oxy)-1-butenyl)cyclopentyl)-5-heptenoate

157283-68-6

5-Heptenoic acid,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-,1-methylethyl ester,(5Z)

AC1NQZOS

AC-6103

AL6221

AL-6221

C26H35F3O6

CHEBI:746859

CHEMBL1200799

CID5282226

D01964

DB00287

Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(a,a,a-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate

Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(a,a,a-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid

isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate

Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate

Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid

isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate

Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate

Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid

LS-173521

propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoate

propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate

S1554_Selleck

Travatan

Travatan (TN)

Travatan Alcon

Travatan Z

Travatan, Travoprost

Travatanz

Travoprost

Travoprost (JAN/USAN/INN)

Travoprost [USAN]

Travoprostum

Z, Travatan

ZINC04474682

Timolol

Approved

Phase 4

26839-75-8

33624 5478

Synonyms:

(-)-3-Morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole

(2S)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol

(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol

(2S)-1-[(1,1-dimethylethyl)amino]-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol

(S)-1-(1,1-(Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol

(S)-1-(tert-Butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol

(S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol

(S)-timolol

131628-37-0

194288-09-0

26839-75-8

26921-17-5 (maleate (1:1) salt)

AB00513729

AC1L1PYN

AC1Q59QM

Apo-Timol

Apo-Timop

Aquanil

Betim

Betimol

Betimol (TN)

BIDD:GT0073

Blocadren

BPBio1_001008

BRD-K08806317-050-03-6

BSPBio_000916

C07141

C13H24N4O3S

CAS-26921-17-5

CHEBI:9599

CHEMBL499

CID33624

CPD001456519

D08600

DB00373

DB08625

EINECS 248-032-6

HMS2089I11

HSDB 6533

Istalol

L-714,465

Lopac0_001189

Lopac-T-6394

LS-122231

MK-950

NCGC00016038-01

NCGC00016038-02

NCGC00016798-01

NCGC00016798-07

NCGC00022033-02

NCGC00022033-04

NCGC00022033-05

Novo-Timol

Nu-Timolol

Oprea1_640981

Optimol

Phoxal-timolol

Prestwick0_000948

Prestwick1_000948

Prestwick2_000948

Prestwick3_000948

Proflax

S-(-)-3-(3-tert-Butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole

S(-)-Timolol maleate

SAM002564238

SPBio_003075

ST072193

Temserin

Tenopt

TIM

Timacar

Timacor

Tim-AK

timolol

Timolol

Timolol (INN)

Timolol (TN)

Timolol [USAN]

Timolol anhydrous

Timolol GFS

Timolol maleate

Timolol Maleate, (1:1) Salt

Timololo

Timololum

Timololum [INN-Latin]

Timopic

Timoptic

Timoptic in Ocudose

Timoptic OcuDose

Timoptic-XE

Timoptol

Tocris-0649

UNII-817W3C6175

Brinzolamide

Approved

Phase 4

138890-62-7

68844

Synonyms:

(+)-4-ETHYLAMINO-3,4-DIHYDRO-2-(METHOXY)PROPYL-2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE-1,1-DIOXIDE

(4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide

(4R)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide

(R)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide

(R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide

138890-62-7

2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide,4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-,1,1-dioxide,R

3znc

AB00513824

AC1L2AKA

AC1Q6UVB

AC-5277

AKOS005145708

AL 4862

AL04862

AL-4862

Alcon brand of brinzolamide

Alcon brand OF brinzolamide

Allphar brand of brinzolamide

Allphar brand OF brinzolamide

Azopt

Azopt (TN)

BIDD:GT0039

Birnzolamide

BPBio1_000539

BRD-K74913225-001-03-3

Brinzolamida

Brinzolamide

Brinzolamide (BRZ)

Brinzolamide (JAN/USP/INN)

Brinzolamide [USAN]

BSPBio_000489

BZ1

C07760

C111827

C12H21N3O5S3

CHEBI:3176

CHEMBL220491

CID68844

D00652

DB01194

FT-0082471

HMS1569I11

I09-0605

LS-173036

MLS002153787

MolPort-005-940-291

Prestwick0_000365

Prestwick1_000365

Prestwick2_000365

Prestwick3_000365

SMR001233169

SPBio_002410

UNII-9451Z89515

Maleic acid

Experimental, Investigational

Phase 4

110-17-8, 110-16-7

444972

Synonyms:

(2E)-2-Butenedioate

(2E)-2-butenedioic acid

(2E)-2-Butenedioic acid

(2E)-But-2-enedioate

(2E)-but-2-enedioic acid

(2E)-But-2-enedioic acid

(e)-2-Butenedioate

(e)-2-Butenedioic acid

(E)-2-butenedioic acid

(E)-2-Butenedioic acid

(E)-but-2-enedioic acid

03761_FLUKA

1,2-Ethylenedicarboxylic acid, (E)

110-17-8

2-(e)-Butenedioate

2-(e)-Butenedioic acid

2-(E)-Butenedioic acid

240745_ALDRICH

240745_SIAL

26B3632D-E93F-4655-90B0-3C17855294BA

2-Butenedioic acid

2-Butenedioic acid (2E)- (9CI)

4-02-00-02202 (Beilstein Handbook Reference)

623158-97-4

AB1002616

AC1L9H76

AC1Q5T7Y

AC1Q71EM

Acidum fumaricum

AI3-24236

AKOS000118896

Allomaleate

Allomaleic acid

Allomalenic acid

ammonium fumarate

Ammonium fumarate

AR-1D9767

bmse000083

Boletate

Boletic acid

BRN 0605763

But-2-enedioic acid

Butenedioic acid

C00122

C4H4O4

Caswell No. 465E

CCRIS 1039

CHEBI:18012

CHEBI:22958

CHEMBL503160

CID444972

D02308

DB04299

e297

E-2-Butenedioic acid

EINECS 203-743-0

EPA Pesticide Chemical Code 051201

F0067

F8509_SIGMA

FC 33

FC 33 (acid)

FEMA No. 2488

FEMA Number 2488

fum

fumarate

Fumarate

fumarate, 10

fumaric acid

Fumaric acid (8CI)

Fumaric acid (NF)

Fumaricum acidum

Fumarsaeure

Fumarsäure

Furamag

HSDB 710

I04-1070

Kyselina fumarova

Kyselina fumarova [Czech]

Lichenate

Lichenic acid

Lichenic acid (VAN)

LMFA01170106

LS-500

Magnesium fumarate

MLS002454406

MolPort-001-780-031

MolPort-004-288-293

NCGC00091192-01

nchembio.186-comp71

nchembio.2007.47-comp1

NSC2752

NSC-2752

OR17920

S04-0167

SMR000112117

Sodium fumarate

trans-1,2-Ethylenedicarboxylate

trans-1,2-ethylenedicarboxylic acid

trans-1,2-Ethylenedicarboxylic acid

trans-2-Butenedioate

trans-2-Butenedioic acid

trans-But-2-enedioate

trans-but-2-enedioic acid

trans-But-2-enedioic acid

trans-Butenedioate

trans-Butenedioic acid

Tumaric acid

U-1149

UNII-88XHZ13131

USAF EK-P-583

W248800_ALDRICH

WLN: QV1U1VQ-T

Autonomic Agents

Phase 4

Muscarinic Agonists

Phase 4

Cholinergic Agents

Phase 4

Antihypertensive Agents

Phase 4

Pharmaceutical Solutions

Phase 4

Ophthalmic Solutions

Phase 4

Neurotransmitter Agents

Phase 4

Anti-Arrhythmia Agents

Phase 4

Adrenergic Agonists

Phase 4

Adrenergic Antagonists

Phase 4

Adrenergic alpha-2 Receptor Agonists

Phase 4

Adrenergic beta-Antagonists

Phase 4

Brimonidine Tartrate, Timolol Maleate Drug Combination

Phase 4

Brimonidine Tartrate

Phase 4

70359-46-5

Adrenergic Agents

Phase 4

Carbonic Anhydrase Inhibitors

Phase 4

Bimatoprost

Approved, Investigational

155206-00-1

5311027

Synonyms:

(5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl}-N-ethylhept-5-enamide

(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide

(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide

155206-00-1

15M

267244-98-4

5-Heptenamide,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ehtyl-,(5Z)

AC1NSJUW

AGN 192024

AGN-192024

Bimataprost [USAN:INN:BAN]

Bimatoprost

Bimatoprost (JAN/USAN/INN)

Bimatoprost [USAN:INN:BAN]

bimatoprostum

Bimatoprostum

CHEBI:39562

CHEBI:51230

CHEMBL1200963

CID5311027

D02724

DB00905

DB06863

I06-1275

I06-1277

Latisse

LS-181817

Lumigan

Lumigan (TN)

NCGC00181745-01

UNII-QXS94885MZ

ZINC04474405

Interventional clinical trials:

(show all 12)

#	Name	Status	NCT ID	Phase	Drugs
1	A Twelve-Week, Double Masked, Parallel Group, Primary-Therapy Pilot Study of the Safety and Efficacy of Travoprost 0.004% Compared to Pilocarpine 1% in Patients With Chronic Angle-Closure Glaucoma	Completed	NCT00762645	Phase 4	Travoprost 0.004% (Travatan);Pilocarpine 1%
2	An 8 Week, Single Masked, Parallel-Group, Exploratory Study Comparing Ocular Surface Signs and Symptoms in Monotherapy Ocular Hypertension or Glaucoma Patients Randomized to Either Xalatan® or Travatan Z®	Completed	NCT00799682	Phase 4	Xalatan;Travatan Z
3	Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients	Terminated	NCT01151904	Phase 4	brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution;latanoprost
4	A Double-Masked, Parallel-Group, Efficacy and Safety Study of Brinzolamide 1.0% (AZOPT) as Adjunctive Therapy to Travoprost 0.004% (TRAVATAN) in Patients With Chronic Angle-Closure Glaucoma	Terminated	NCT00758342	Phase 4	Travoprost 0.004% + Brinzolamide 1.0%;Travoprost 0.004% + Tears Natural
5	A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma.	Completed	NCT00051181	Phase 3	Travoprost (0.004%);Latanoprost (0.005%)
6	A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma	Unknown status	NCT02152774	Phase 2	Rho-Kinase Inhibitor
7	Prevalence of Chronic Angle Closure in Caucasian Hyperopic Subjects	Unknown status	NCT00823706
8	Comparison of Bimatoprost and Lataprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study	Unknown status	NCT00567788		Latanoprost-Bimatoprost;Bimatoporost-Latanoprost
9	Biometric Indicators of Eyes With Occult Lens Subluxation	Completed	NCT03752710
10	Angle Closure: Laser Iridotomy Versus Phacoemulsification Study (ACLIPS)- A Study of Acute Primary Angle Closure Glaucoma Comparing Two Treatment Modalities: Laser Peripheral vs Phacoemulsification With Posterior Intraocular Lens Implant	Completed	NCT00350428
11	Comparison Study of Glaucoma Eye Care Follow-Up Adherence in a High Risk Population	Completed	NCT02347670
12	Sequential Laser Iridotomy Using Argon and Q-Switched 532 nm Frequency Doubled Neodymium Yag Laser: A Pilot Study	Completed	NCT00452998

Search NIH Clinical Center for Chronic Closed-Angle Glaucoma

Sources

Genetic Tests for Chronic Closed-Angle Glaucoma

Sources

Anatomical Context for Chronic Closed-Angle Glaucoma

MalaCards organs/tissues related to Chronic Closed-Angle Glaucoma:

⁴⁰

Eye, Testes, Endothelial

Sources

Publications for Chronic Closed-Angle Glaucoma

Articles related to Chronic Closed-Angle Glaucoma:

(show top 50) (show all 320)

#	Title	Authors	PMID	Year
1	A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. ⁵⁴ ⁶¹	CAT-152 0102 Trabeculectomy Study Group...Smith Z	17908591	2007
2	Aqueous humor levels of TGFβ2 and SFRP1 in different types of glaucoma. ⁶¹	Guo T...Fan X	31382918	2019
3	Differential Efficacy of Combined Phacoemulsification and Endocyclophotocoagulation in Open-angle Glaucoma Versus Angle-closure Glaucoma. ⁶¹	Lin MM...Chen TC	30839415	2019
4	Anterior Segment Features in Nanophthalmos With Secondary Chronic Angle Closure Glaucoma: An Ultrasound Biomicroscopy Study. ⁶¹	Guo C...Fan Z	31112609	2019
5	Early results of micropulse transscleral cyclophotocoagulation for the treatment of glaucoma. ⁶¹	Nguyen AT...Noecker RJ	30938190	2019
6	Surgical outcomes of phacoemulsification/goniosynechialysis with and without endocyclophotocoagulation in patients with chronic angle closure glaucoma. ⁶¹	Panse K...Ayyala RS	30777954	2019
7	Primary Outcomes of Patients with Chronic Angle-Closure Glaucoma Treated with Combined Phacoemulsification, Viscogoniosynechialysis, and Endocyclophotocoagulation. ⁶¹	Izquierdo Villavicencio JC...Mejias Smith J	31312531	2019
8	Post-miosis changes in the anterior chamber structures in primary and lens-induced secondary chronic angle-closure glaucoma. ⁶¹	Li M...Zhang H	31024825	2019
9	Indicating and predicting role of the horizontal C/D ratio in preclinical diabetic retinopathy associated with chronic angle-closure glaucoma. ⁶¹	Zhong ZL...Chen S	30809483	2019
10	RETINAL AND CHOROIDAL VASCULAR OCCLUSION FOLLOWING AQUEOUS MISDIRECTION SYNDROME IN A PATIENT WITH SICKLE CELL TRAIT. ⁶¹	Dewundara S...Abrams GW	28489705	2019
11	Cypass Supraciliary Stent in Eye With Chronic Angle Closure and Postvitrectomy With Silicone Oil. ⁶¹	Hopen ML...Gallardo MJ	29979341	2018
12	Profile and management outcomes of glaucoma cases at Qassim University Hospital. ⁶¹	Alzuhairy S...Mousa A	30202404	2018
13	Angle-closure Glaucoma in a Myopic Patient Precipitated by Sexual Excitation: A Case Report. ⁶¹	Popovic M...Schlenker MB	31354207	2018
14	Factors Associated with Outcomes of Combined Phacoemulsification and Ahmed Glaucoma Valve Implantation. ⁶¹	Kwon J...Sung KR	29770636	2018
15	Retinal pigment epithelium changes in Kartagener syndrome. ⁶¹	Garcia MD...Berrocal AM	29511746	2018
16	Long-term outcomes after acute primary angle closure of Caucasian chronic angle closure glaucoma patients. ⁶¹	Fea AM...Aung T	28722309	2018
17	Macular Choroidal Small-Vessel Layer, Sattler's Layer and Haller's Layer Thicknesses: The Beijing Eye Study. ⁶¹	Zhao J...Jonas JB	29535365	2018
18	Refractive outcomes of phacoemulsification cataract surgery in glaucoma patients. ⁶¹	Manoharan N...Seibold LK	29605284	2018
19	Visual Subfield Progression in Glaucoma Subtypes. ⁶¹	Su WW...Chen HS	29750123	2018
20	Longitudinal Change in Peripheral Anterior Chamber Depth of Eyes with Angle Closure after Laser Iridotomy. ⁶¹	Furuya T...Kashiwagi K	30671261	2018
21	Ocular pulse amplitude in different types of glaucoma using dynamic contour tonometry: Diagnosis and follow-up of glaucoma. ⁶¹	Cheng L...Wu Z	29104631	2017
22	Optic Nerve Head Characteristics in Chronic Angle Closure Glaucoma Detected by Swept-Source OCT. ⁶¹	Li D...Shen LQ	28922031	2017
23	Long-term scanning laser ophthalmoscopy and perimetry in different severities of primary open and chronic angle closure glaucoma eyes. ⁶¹	Sihota R...Kalaiwani M	29044061	2017
24	Acute hypotony maculopathy following the initiation of a topical aqueous suppressant in a patient with a history of panuveitis without prior filtering surgery. ⁶¹	Zhu D...Rao NA	29260088	2017
25	Intraoperative Optical Coherence Tomography-Assisted Descemet Stripping Automated Endothelial Keratoplasty for Anterior Chamber Fibrous Ingrowth. ⁶¹	Shazly TA...Espandar L	28399038	2017
26	High intensity focused ultrasound as first line treatment in patients with chronic angle closure glaucoma at risk for malignant glaucoma. ⁶¹	Graber M...Lachkar Y	28342558	2017
27	Analyzing cytokines as biomarkers to evaluate severity of glaucoma. ⁶¹	Tong Y...Wang ZY	28730084	2017
28	Peripapillary retinal splitting visualized on OCT in glaucoma and glaucoma suspect patients. ⁶¹	Grewal DS...Tanna AP	28832670	2017
29	Bilateral Same-day Laser Peripheral Iridotomy in the Philadelphia Glaucoma Detection and Treatment Project. ⁶¹	Waisbourd M...Katz LJ	26950579	2016
30	Pupillary block due to reverse implantation of a sulcus intraocular lens. ⁶¹	Zhang X...Saeedi O	28184333	2016
31	Intraoperative floppy-iris syndrome associated with use of antipsychotic drugs. ⁶¹	Matsuo M...Tanito M	27521670	2016
32	Risk Factors of Disease Progression After Cataract Surgery in Chronic Angle-closure Glaucoma Patients. ⁶¹	Lee CK...Kim CY	26550967	2016
33	Efficacy and Safety of Trabectome Surgery in Chinese Open-Angle Glaucoma. ⁶¹	Lee JW...Lai JS	27082559	2016
34	Endoscopic Cyclophotocoagulation and Pars Plana Ablation (ECP-plus) to Treat Refractory Glaucoma. ⁶¹	Tan JC...Chopra V	26020690	2016
35	The Frequency of Optical Coherence Tomography Testing in Glaucoma at a Single Academic Medical Center. ⁶¹	Griffith JF...Goldberg JL	26372155	2016
36	The effect of adjustable suture (Khaw) trabeculectomy on intraocular pressure: a retrospective case series. ⁶¹	Kaplan A...Dayanir V	26002838	2016
37	Case report: imaging and treatment of ophthalmic manifestations in oculodentodigital dysplasia. ⁶¹	Mosaed S...Lin KY	26743931	2016
38	Comparison of phacotrabeculectomy and sequential surgery in the treatment of chronic angle-closure glaucoma coexisted with cataract. ⁶¹	Li HJ...Xie L	27275422	2016
39	The safety and efficacy of modified minimally invasive trabeculectomy for the treatment of primary chronic angle-closure glaucoma. ⁶¹	Wu Z...Ma D	27215005	2015
40	Rapid anterior capsular phimosis after cataract surgery in a patient with chronic angle closure glaucoma. ⁶¹	Chang PY...Chang SW	29018698	2015
41	Transscleral cyclophotocoagulation in refractory acute and chronic angle closure glaucoma. ⁶¹	Yusuf IH...James CB	26424819	2015
42	Effect of Goniosynechialysis During Phacoemulsification on IOP in Patients With Medically Well-controlled Chronic Angle-Closure Glaucoma. ⁶¹	Lee CK...Kim CY	25387342	2015
43	Diode laser cyclophotocoagulation for nanophthalmic chronic angle closure glaucoma. ⁶¹	Golan S...Kurtz S	23807357	2015
44	Prevalence of comorbid retinal disease in patients with glaucoma at an academic medical center. ⁶¹	Griffith JF...Goldberg JL	26203217	2015
45	Diffusion tensor imaging of optic nerve and optic radiation in primary chronic angle-closure glaucoma using 3T magnetic resonance imaging. ⁶¹	Zhang QJ...Li XH	26558212	2015
46	Meta-analysis of randomized controlled trials comparing latanoprost with other glaucoma medications in chronic angle-closure glaucoma. ⁶¹	Li J...Yu M	25044139	2015
47	T-helper1/T-helper2 cytokine imbalance in the iris of patients with glaucoma. ⁶¹	Wong M...Zhang C	25811482	2015
48	Delayed diagnosis of subacute angle closure glaucoma in patients presenting with headaches. ⁶¹	Nesher R...Segal O	24677021	2014
49	Reduced intraocular pressure after cataract surgery in patients with narrow angles and chronic angle-closure glaucoma. ⁶¹	Brown RH...Hovis KL	25134991	2014
50	Effectivity of Nd Yag PI in treatment of acute primary angle closure glaucoma. ⁶¹	Singh P...Rijal AP	25799811	2014

Sources

Genes for Chronic Closed-Angle Glaucoma

Genes related to Chronic Closed-Angle Glaucoma (0 elite genes):

(show all 13)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	TGFB2	Transforming Growth Factor Beta 2	Protein Coding	11.8	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	17908591
2	NARF	Nuclear Prelamin A Recognition Factor	Protein Coding	5.97	DISEASES inferred ¹⁵
3	PRELID1	PRELI Domain Containing 1	Protein Coding	5.95	DISEASES inferred ¹⁵
4	SPATA31A3	SPATA31 Subfamily A Member 3	Protein Coding	5.92	DISEASES inferred ¹⁵
5	LOXL1	Lysyl Oxidase Like 1	Protein Coding	5.92	DISEASES inferred ¹⁵
6	MYOC	Myocilin	Protein Coding	5.77	DISEASES inferred ¹⁵
7	CTSA	Cathepsin A	Protein Coding	5.63	DISEASES inferred ¹⁵
8	LAMA3	Laminin Subunit Alpha 3	Protein Coding	5.47	DISEASES inferred ¹⁵
9	PANX3	Pannexin 3	Protein Coding	5.08	DISEASES inferred ¹⁵
10	TCEA1	Transcription Elongation Factor A1	Protein Coding	5.06	DISEASES inferred ¹⁵
11	IZUMO2	IZUMO Family Member 2	Protein Coding	5.05	DISEASES inferred ¹⁵
12	CYLC2	Cylicin 2	Protein Coding	5.01	DISEASES inferred ¹⁵
13	PANX2	Pannexin 2	Protein Coding	4.91	DISEASES inferred ¹⁵

Sources

Variations for Chronic Closed-Angle Glaucoma

Sources

Expression for Chronic Closed-Angle Glaucoma

Search GEO for disease gene expression data for Chronic Closed-Angle Glaucoma.

Sources

Pathways for Chronic Closed-Angle Glaucoma

Pathways related to Chronic Closed-Angle Glaucoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	ECM proteoglycans ⁶⁵	10.38	TGFB2 LAMA3

Sources

GO Terms for Chronic Closed-Angle Glaucoma

Cellular components related to Chronic Closed-Angle Glaucoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	gap junction	GO:0005921	8.96	PANX3 PANX2
2	collagen-containing extracellular matrix	GO:0062023	8.92	TGFB2 MYOC LOXL1 LAMA3

Biological processes related to Chronic Closed-Angle Glaucoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein hexamerization	GO:0034214	8.96	PANX3 PANX2
2	positive regulation of interleukin-1 secretion	GO:0050716	8.62	PANX3 PANX2

Molecular functions related to Chronic Closed-Angle Glaucoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	channel activity	GO:0015267	9.16	PANX3 PANX2
2	gap junction hemi-channel activity	GO:0055077	8.96	PANX3 PANX2
3	wide pore channel activity	GO:0022829	8.62	PANX3 PANX2

Sources

Sources for Chronic Closed-Angle Glaucoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia